Series A · Biotech · Oslo, Norway · Founded 2021 · 1–10 employees
Actithera is a radiopharmaceutical biotechnology company that develops next-generation radioligand therapies for cancer treatment. Under the leadership of founder Dr. Andreas Goutopoulos, the company utilizes a proprietary molecular design platform that integrates medicinal chemistry and radiochemistry. Their technology is engineered to maximize tumor retention of targeted therapeutics while ensuring rapid clearance from healthy tissues. In July 2025, the company secured a $75.5 million Series A funding round to advance its pipeline. Additionally, the company secured an exclusive licensing agreement with Yeda in October 2025 to integrate breakthrough covalent chemistry technologies.
No open roles listed right now.